Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Entourage Health Corp V.ENTG

Alternate Symbol(s):  ETRGF

Entourage Health Corp. is a Canada-based license holder producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 26,000 square feet indoor facility in Aylmer, Ontario (the Aylmer Facility), specializing in product development and fulfillment for both adult-use and medical cannabis. The Company is focused on building a portfolio of... see more

TSXV:ENTG - Post Discussion

Entourage Health Corp > Preliminary Q3 Record Revenue of $14.7 Million
View:
Post by Betteryear2 on Oct 19, 2021 8:39am

Preliminary Q3 Record Revenue of $14.7 Million

  • Fourth consecutive quarter of growth attributed to expanding market share and record sales
  • Company also completes amendments to its $39 million senior secured credit facility

TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG(OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products and brands, is pleased to announce its preliminary unaudited total revenues of $14.7 million(1) for the three months ended September 30, 2021, representing another quarter of sequential record sales growth across its adult-use and medical sales channels.

The Company plans to file its third quarter 2021 financial statements and management’s discussion and analysis pre-market on Tuesday, November 16, 2021. Entourage will host a conference call at 10 a.m. Eastern Time same day to review the results, provide an operational update and discuss recent milestones.

“Over the past four quarters, we’ve continued to see improved costs, expanded margins, and most critically, continued demand for our products – all of which are contributing to a meaningful gain in market share and a consistent increase in our quarterly sales,” said George Scorsis, Interim CEO and Executive Chair. “Our Q3 preliminary revenue results demonstrate approximately 90% revenue improvement year-over-year as we continue executing our transformation and site optimization initiatives to bring more high-margin products to market. With the previously announced acquisition of craft cultivator CannTx Life Sciences expected to close imminently, we’re thrilled to be introducing “craft” cultivars and products into our distribution network for our medical clients and adult-use consumers – all of which will also bring expanded value for our shareholders.”

Conference Call Details:

The conference call will be hosted by Mr. Scorsis and Entourage’s CFO, Beth Carreon. Management will be available for questions following opening remarks.

Date: Tuesday, November 16, 2021
Time: 10 a.m. Eastern Time
Dial-in Number: Canada/USA: 1-800-319-4610. International Toll: 1-604-638-5340
Participants, please dial in and ask to join the Entourage call
Replay Dial-in: Canada/USA: 1-800-319-6413. International Toll: 1-604-638-9010
Replay Access Code: 7966
Available after 12:00 p.m. Eastern Time, until December 16, 2021

Visit Entourage Health’s newly launched website here. To access our corporate video, visit us here and to access our latest investor presentation and corporate deck here.

Amendment to Credit Facility

The Company also confirmed today is has signed an additional amendment to its senior secured credit facility entered into on March 29, 2019 (the “Credit Facility”). The latest amendments to the Credit Facility modify the terms under which Entourage secured up to $39 million of debt financing over a three-year term ending in 2022.

Under the terms of the amendment, the Company secured a deferral of certain of its financial covenants to December 31, 2021. In addition, the Company has agreed to a 25 basis point increase in the applicable interest rate margin on the Credit Facility, which continues to provide Entourage with non-dilutive, tier-one bank financing and greater financial flexibility in alignment with market conditions. A copy of the conformed Credit Facility agreement will be made available on the Company’s SEDAR page.


https://www.globenewswire.com/news-release/2021/10/19/2316572/0/en/Entourage-Health-Announces-Preliminary-Q3-Record-Revenue-of-14-7-Million-and-Confirms-Financial-Results-Call-to-be-Held-on-November-16-2021-at-10-a-m-ET.html
Comment by Ebankbank on Oct 19, 2021 9:01am
Great to see 4 consecutive quarter of growth!!!! Now let's see our investment grow ? Would be awesome to get back north of $1.00
Comment by InvestingFool50 on Oct 19, 2021 9:15am
Yes would be, let's see how the market reacts. We all know how one will on here. I do have him on ignore. May have to change that to see how he puts this news down.
Comment by Nicksonsnowboar on Oct 19, 2021 1:37pm
Nope , the joke continues  , only weed stock looking for new lows as others are up by as much as 10:1 ratio. Every NR produces a negative affect which usually indicates a lack of faith  and trust in management.People can't even bail at .16 . Where is Moe!
Comment by Wrywisdom on Oct 19, 2021 1:39pm
Yes, an absolutely incredible opportunity for new investors to realize massive profits entering here at ground level. Just $1.00 as you mentioned, yields a 600%+ return. Cumulative revenues for just one year are presently equal approximately to current valuation, with revenues growing each quarter. Also, the the truly perfect time to cost average. We can see this company has undergone careful ...more  
Comment by Nicksonsnowboar on Oct 19, 2021 1:46pm
Wishful thinking , should end up at .15  today and that is being optimistic  . There has been a change make that a 15:1 ratio. Like I said they are consistent unfortunately to the downside. 
Comment by InvestingFool50 on Oct 19, 2021 9:12am
Without the benefit of Cann. Let's see if was worth the move. I do believe was a good thing. Next quarter should be with everything fireing on all cylinders.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities